Paraoxonase Activity In Patients With Chronic Obstructive Pulmonary Disease

Year 2021, Volume: 3 Issue: 2, 64 - 68, 31.08.2021

Kerim Yeşildağ , Turgut Teke , Sami Erdem

Abstract

Aim: We aimed to study the Paraoxonase 1 (PON1) activity in chronic obstructive pulmonary disease (COPD) patients with stable condition, had acute attack and developed respiratory failure. Material and Method: Twenty-five patients with stable COPD (group1) (mean age 62.9±9.4), 25 cases with acute COPD attack (group2) (mean age 63.8±9.0), 25 patients with hypercapnic respiratory failure (group3) (mean age 65.0±12.9) and 25 healthy individuals for control group (mean age 34.8±9.8), totally 100 cases, were enrolled to the study. Cases with secondary lipid disorder, cardiovascular disease, diabetes mellitus, renal failure, malignancy, hepatic failure and patients who receive antilipidemic or antioxidant medicines were not included to the study. All cases enrolled to the study underwent routine biochemical analysis including PON1 activity and lipid profile. Results: There was significant difference between groups with respect to PON1 levels (p<0.0001). PON1 activities of COPD patient groups (group 1=96.8±57.4U/L; group 2=51.4±32.8U/L; group 3=47.1±27.5U/L) were lower than control group (185.4±110.1U/L) (p<0.0001). Also, PON1 activity of stable COPD patients was higher than the COPD cases admitted with acute attack or respiratory failure (group2 and 3) (p<0.05). Conclusion: These findings show that PON1 activity may have a role in COPD pathogenesis and endogen antioxidants might be depleted by increased oxidative stress in COPD. This also advocates that oxidative stress may have a role in acute COPD attacks.

Keywords

COPD, oxidative stress, Paraoxonase

References

• 1. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med . 2021 Jan 1;203(1):24-36. doi: 10.1164/rccm. 202009-3533SO.
• 2. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50–60
• 3. Salari N, Rasoulpoor S, Hosseinian-Far A, Razazian N, Mansouri K, Mohammadi M. et al. Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review. Neurol Sci. 2021 Feb;42(2):491- 500. doi: 10.1007/s10072-020-04842-3.
• 4. Rodrigo L, Hernández AF, López-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact. 2001 Aug 31;137(2):123-37. doi: 10.1016/s0009- 2797(01)00225-3.
• 5. Sarioglu N, Bilen C, Cevik C, et al. Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease. Eurasian J Med 2020; 52(2): 161-5.
• 6. Mango, Gregory W., Carl J. Johnston, Susan D. Reynolds, Jacob N. Finkelstein, Charles G. Plopper, and Barry R. Stripp. Clara cell secretory protein deficiency increases oxidant stress response in conducting airways. Am. J. Physiol. 275 (Lung Cell. Mol. Physiol. 19
• 7. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, et al Human serum paraoxonase (PON 1) is inactivated by oxidized low-density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26(7–8):892–904
• 8. Leray E, Moreau T, Fromont A, Edan A (2016) Epidemiology of multiple sclerosis. Rev Neurol (Paris) 172(1):3–13
• 9. Hadjigeorgiou GM, Malizos K, Dardiotis E, Aggelakis K, Dardioti M, Zibis A, et al. Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J Orthop Res 2017;25(8):1087–1093
• 10. Compston A, Coles A. Multiple sclerosis. Lancet (Lond, Engl) 2008;372:1502–1517
• 11. Menini T, Gugliucci A. Paraoxonase 1 in neurological disorders. Redox Rep 2014;19(2):49–58
• 12. Acay A, Erdenen F, Altunoglu E, Erman H, Muderrisoglu C, Korkmaz G G, et al. Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease. Clin Lab . 2013;59(11-12):1331-7. doi: 10.7754/clin.lab.2013.121144
• 13. Lada Rumora 1, Marija Grdić Rajković, Lara Milevoj Kopčinović, Dolores Pancirov, Ivana Č epelak, Tihana Žanić Grubišić. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease. COPD. 2014 Sep;11(5):539-45. doi: 10.3109/15412555.2014.898028
• 14. Kunutsor SK, Kieneker LM, Bakker SJL, et al. The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study. Atherosclerosis 2017; 263: 219-26
• 15. Karakaya P, Ozdemir B, Mert M, et al. Relation of Paraoxonase 1 activity with biochemical variables, brachial artery intima- media thickness in patients with diabetes with or without obesity. Obes Facts 2018; 11: 56-66
• 16. Viktorinova A, Jurkovicova I, Fabryova L, et al. Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in Type 2 diabetes. Diabetes Res Clin Pract 2018; 140: 174-82
• 17. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and non-smokers. Inhal Toxicol. 2007; 19: 767-9. [Crossref]
• 18. Isik B, Isik RS, Ceylan A, et al. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudi Med J 2005; 26: 1882-5.
• 19. Senti M, Tomás M, Anglada R, et al. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med 2003; 14: 178-84. [Crossref])
• 20. Sepahvand F, Shafiei M, Ghaffari SM, et al. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol 2007; 101: 104-7.